Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Logothetis

Showing results (341-350 of 383) with videos related to

Pageof 39
Sort By:
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) SeriesNicolas Anselmino, Estefania Labanca, Peter D A Shepherd, et al.
Science Translational Medicine|September 5, 2014
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesXinhai Wan, Paul G Corn, Jun Yang, et al.
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The Journal of Urology|September 10, 2021
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional CohortLauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, et al.
European Urology Oncology|November 18, 2021
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial CancerOmar Alhalabi, Yueting Zhu, Ameer Hamza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate CancerSusan Halabi, William Kevin Kelly, Hua Ma, et al.
European Urology|December 21, 2017
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants MeetingJun Luo, Gerhardt Attard, Steven P Balk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2020
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy DevelopmentNallasivam Palanisamy, Jun Yang, Peter D A Shepherd, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancerFortunato Ferrara, Daniela I Staquicini, Wouter H P Driessen, et al.
Pageof 39

Showing results (341-350 of 383) with videos related to

Sort By:
Pageof 39
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) SeriesNicolas Anselmino, Estefania Labanca, Peter D A Shepherd, et al.
Science Translational Medicine|September 5, 2014
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesXinhai Wan, Paul G Corn, Jun Yang, et al.
European Urology|May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
The Journal of Urology|September 10, 2021
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional CohortLauren Folgosa Cooley, Adaeze A Emeka, Travis J Meyers, et al.
European Urology Oncology|November 18, 2021
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial CancerOmar Alhalabi, Yueting Zhu, Ameer Hamza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate CancerSusan Halabi, William Kevin Kelly, Hua Ma, et al.
European Urology|December 21, 2017
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants MeetingJun Luo, Gerhardt Attard, Steven P Balk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2020
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy DevelopmentNallasivam Palanisamy, Jun Yang, Peter D A Shepherd, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancerFortunato Ferrara, Daniela I Staquicini, Wouter H P Driessen, et al.
Pageof 39